Trial Profile

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary) ; Decitabine (Primary) ; Sabatolimab (Primary) ; Spartalizumab (Primary) ; Venetoclax (Primary)
Indications Myelodysplastic syndromes
Focus Adverse reactions
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

28 Feb 2025 Planned End Date changed from 5 Nov 2025 to 14 Feb 2028.
28 Feb 2025 Planned primary completion date changed from 5 Nov 2025 to 14 Feb 2028.
14 Feb 2025 Planned End Date changed from 14 Feb 2028 to 5 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com